1) plasminogen activator inhibitor-1/tissue plasminogen activator
纤溶酶原激活物抑制物-1/组织纤溶酶原激活物
2) t-PA/PAI-1
组织型纤溶酶原激活物/纤溶酶原激活抑制物-1
3) PAI-1
组织型纤溶酶原激活物抑制物-1
1.
Study of relationship between insulin resistance and activity of PAI-1 in patients with cerebral infarction;
脑梗死患者的胰岛素抵抗与血浆组织型纤溶酶原激活物抑制物-1活性相关性的研究
4) plasminogen activator inhibitor 1
纤溶酶原激活抑制物1
5) atherrosclerosis
纤溶酶原激活抑制物-1
1.
Objective Raising atherrosclerosis model, to observe the the local expression of angiotensin II (Ang II ), transforming growth factor-β1 (TGF-β1)、plasminogen activator inhibitor-1 (PAI-1) and type IV collagen in renal tissue and to approach the renal protective effect of Captopril and Valsartan through blocking renin-angiotonin system(RAS) on various level.
目的建立动脉粥样硬化(atherosclerosis,AS)模型,观察在AS形成时肾脏组织中血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)、转化生长因子-β1(transforming growth factor-β1,TGF-β1)、纤溶酶原激活抑制物-1(plasminogen activator inhibitor-1,PAI-1)和Ⅳ型胶原蛋白的表达以及卡托普利与缬沙坦从不同水平阻断肾素-血管紧张素系统(renin-angiotonin system,RAS)后对肾脏的保护作用。
6) Tissue plasminogen activactor/plasminogen activator inhibitor-1
组织型纤溶酶原激活物／1型纤溶酶原激活物抑制物
补充资料：物竞天择
见进化论。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条